NCT01667575

Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to observe the efficacy of ten day triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment.

Detailed description

The success rate of currently recommended triple therapy with a proton pump inhibitor (PPI) plus amoxicillin and clarithromycin has fallen into the unacceptable range. The purpose of this study is to observe the efficacy of ten day triple therapy-based, bismuth-containing quadruple therapy for H.pylori treatment, while ten day triple therapy is used as control.

Conditions

• Functional Dyspepsia
• Peptic Ulcer
• Helicobacter Pylori

Interventions

Type	Name	Description
DRUG	Esomeprazole	antisecretary drug of the quadruple therapy
DRUG	Amoxicillin	antibiotic of the quadruple therapy
DRUG	Clarithromycin	antibiotic of the quadruple therapy
DRUG	Bismuth Potassium Citrate	one of a component of a quadruple therapy
OTHER	long duration (14 day)

Timeline

• Start date: 2012-08-01
• Primary completion: 2013-05-01
• Completion: 2013-05-01
• First posted: 2012-08-17
• Last updated: 2013-06-04

Locations

1 site across 1 country: China